Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Evalen 0.1% gel

Ferron Par Pharmaceuticals

Ingredients in every g

Adapalene 1 mg

Each package contains

1 tube of 10 g

Dosage form

gel

Dosage formGel

Flavour

None

W.H.O. classification

D10A
D10A

A.T.C. Level 1

Anatomical Main group

D - Dermatologicals
D10A

A.T.C. Level 2

Therapeutic subgroup

D10 - Anti-Acne Preparations
D10A

A.T.C. Level 3

Pharmacological subgroup

D10A - Anti-Acne Preparations for Topical Use

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Indication

Acne vulgaris
Evalen gel 0.1% is used topically for the treatment of moderate to severe Acne Vulgaris

Dosage

12 YEARS OLD AND ABOVE
Evalen gel 0.1% should be applied to the cleansed affected areas of the skin, once daily in the evening at bedtime. A thin film of Evalen gel 0.1% should be applied, avoiding contact with the eyes, lip, angle of the nose and mucous membranes. If product enters the eye, wash immediately with warm water. Ensure that the affected areas are dry before application.

During the early weeks of therapy, an apparent exacerbation of acne may occur. This effect is attributable to the action of the drug on previously unseen lesions and should not be considered a reason to discontinue therapy.

Since it is customary to alternate therapies in the treatment of acne, it is recommended that the physician assess improvement of patient disease after 3 months of treatment with Evalen gel 0.1%.

Patients who is necessary to reduce the frequency of application or to temporarily discontinue treatment, frequency of application may be restored or therapy resumed once it is judged that the patient can again tolerate the treatment.